<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246569</url>
  </required_header>
  <id_info>
    <org_study_id>14-001</org_study_id>
    <nct_id>NCT02246569</nct_id>
  </id_info>
  <brief_title>Lung Volume Reduction Via Coils in Patients With COPD</brief_title>
  <official_title>Impact of Endoscopic Lung Volume Reduction Via Coils on Inspiratory Muscle Strength in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with emphysema lung volume reduction (ELVR) could be an expedient approach for&#xD;
      the reduction of distension of the lung. ELVR may be performed using RePneu® Coils. After the&#xD;
      insertion of the coils distended lung sections shrink so that healthy parts can expand.&#xD;
&#xD;
      In the present study investigators intend to examine, whether the insertion of the coils&#xD;
      improves diaphragm function and force of the breathing muscles. Investigators hypothesize&#xD;
      that reduction of lung volume eliminates or reduces flattening of the diaphragm and relieves&#xD;
      breathing muscles, respectively respiratory pump, which aims to reduce dyspnea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In line with routine explorations it is necessary to clarify whether a patient is suitable&#xD;
      for the endoscopic lung volume reduction. To address this question lung function diagnostics,&#xD;
      6-minutes-walk-test, blood withdrawal, CT of the thorax, lung perfusion scintigraphy and&#xD;
      transthoracic echocardiography have to be performed.&#xD;
&#xD;
      After confirmation of the suitability for the endoscopic lung volume reduction patients who&#xD;
      fulfill all other eligibility criteria will be educated about the aim and performance of the&#xD;
      study by an investigator. After reading the patient information patient may submit his&#xD;
      informed written consent. After that information on the risks will be given by a treating&#xD;
      physician.&#xD;
&#xD;
      Following examination will be performed additional due to the study: determination of the&#xD;
      strength of breathing muscles, determination of the life quality index via&#xD;
      St.-George-questionary and determination of the depression score via SF-8-questionary (short&#xD;
      form-8).&#xD;
&#xD;
      After that coils will be implanted and a permanent post-operative examination will be&#xD;
      performed for 24 hours.&#xD;
&#xD;
      Three, respectively nine month after the implanting follow up exploration will be performed&#xD;
      on the study patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>breathing strength</measure>
    <time_frame>Change of breathing strength 3 (respectively 9) months after the bronchoscopy</time_frame>
    <description>Maximal Inspiratory Pressure (PImax) Maximal Expiratory Pressure (PEmax) Neuromuscular drive (P0.1) Sniff nasal pressure</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with severe COPD (GOLD stage III or IV)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  bilateral lung emphysema after CT with sufficient amount of tissue to perform RePneu&#xD;
             Coil implantation at the discretion of the treating physicians&#xD;
&#xD;
          -  homogeneous or heterogeneous emphysema&#xD;
&#xD;
          -  previous guidelines-based therapy of COPD (including vaccinations against Pneumococcal&#xD;
             infections and seasonal influenza)&#xD;
&#xD;
          -  nicotine abstention for not less than three months, documented by CO-HB (haemoglobin)&#xD;
             &lt; 2%&#xD;
&#xD;
          -  FEV 1 (Forced Expiratory Volume 1 / one second capacity) ≤ 45% of reference value,&#xD;
             after bronchodilatation&#xD;
&#xD;
          -  total lung capacity (TLC) ≥ 100% of reference value&#xD;
&#xD;
          -  residual volume (RV) ≥ 175% of reference value&#xD;
&#xD;
          -  patient's suitability for endoscopic lung volume reduction according to&#xD;
             multidisciplinary decision of pneumology and thorax surgery division.&#xD;
&#xD;
          -  signed Informed Consent&#xD;
&#xD;
          -  understanding of the nature, significance and implications of the study&#xD;
&#xD;
          -  ability to understand and follow instructions of the study stuff&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  echo-cardiographic right ventricular pressure (PAPsys) &gt; 50 mmHg&#xD;
&#xD;
          -  indication for a permanent anticoagulation therapy (besides ASS)&#xD;
&#xD;
          -  pulmonal cachexia&#xD;
&#xD;
          -  pregnancy and lactating&#xD;
&#xD;
          -  permanent treatment with &gt; 20 mg Prednison per day&#xD;
&#xD;
          -  hospitalisation due to a COPD-exacerbation in the last 3 months&#xD;
&#xD;
          -  &gt; 3 steroid-treated exacerbations in the last year&#xD;
&#xD;
          -  Increase of FEV1 (Forced Expiratory Volume) ≥ 20% after bronchodilatation&#xD;
&#xD;
          -  severe diffusion impairment (DLCO &lt; 20%)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Dreher, Univ.-Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH University Hospital MK1</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Dreher, Univ.-Prof.</last_name>
    <phone>+49241 80 88763</phone>
    <email>mdreher@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tobias Müller, PD Dr.med.</last_name>
    <phone>+49241 80 88763</phone>
    <email>tobmueller@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RWTH Univerity Hospital MK1</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dreher, Univ.-Prof.</last_name>
      <phone>+492418088763</phone>
      <email>mdreher@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Tobias Müller, PD Dr.med.</last_name>
      <phone>+492418088763</phone>
      <email>tobmueller@ukaachen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>September 11, 2014</study_first_submitted>
  <study_first_submitted_qc>September 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2014</study_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
  <keyword>endoscopic lung volume reduction</keyword>
  <keyword>RePneu®Coils</keyword>
  <keyword>physical capacity</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

